Last reviewed · How we verify

NCT05963321: ctDCS

Cortical Excitability Modulation With ctDCS in Fibromyalgia.

Active, enrolled NA Last updated 14 January 2026
What this trial tests

NA trial testing TDCS in Fibromyalgia in 92 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 June 2023
Primary endpoint
31 December 2024
1 April 2026

Quick facts

Lead sponsorHospital de Clinicas de Porto Alegre
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment92
Start date15 June 2023
Primary completion31 December 2024
Estimated completion1 April 2026
Sites2 locations across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Hospital de Clinicas de Porto Alegre

Who can join

Adults 18 to 65, female only, with Fibromyalgia or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fibromyalgia is a syndrome characterized by chronic generalized musculoskeletal pain, accompanied by other symptoms such as fatigue, sleep disturbance and depression. Complaints of memory deficit, cognitive dysfunction, headache and gastrointestinal disorders are also common. Although it is a relatively common syndrome, exist a limited effectiveness of the pharmacologycal treatment. However, In the last years new therapeutic and diagnostic options have been sought. This scenario includes the use of different techniques of non-invasive brain stimulation, such as transcranial direct current magnetic stimulation (tDCS) and transcranial magnetic stimulation (TMS), which have already had promising results in reducing pain. Based on the above, the objective of this research is to evaluate the effect of cerebellar tDCS on clinical measures of pain and cortical excitability in patients with fibromyalgia. In this study, the intervention consists of a single tDCS session in which two devices will be used simultaneously. The active electrode will be placed in the cerebellum and/or in the primary motor cortex and the cathode in the contralateral supraorbital region. It is expected that the application of this protocol will be able to have a modulatory effect on clinical pain measures. In addition to producing changes in cortical excitability as a reflection of the integration between the cerebellum-thalamus-cortical pathways.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cortical excitability and analgesic effects of multisite transcranial direct current stimulation targeting the motor cortex and cerebellum in fibromyalgia.
    Betancur DFA, da Graça Lopes Tarragó M, França BR, Bueno GB, et al · · 2025 · PMID 41130992 · DOI 10.1038/s41598-025-20769-1

Verify or expand the search:

Other trials of TDCS

Trials testing the same drug.

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other Hospital de Clinicas de Porto Alegre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05963321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing